Article Sidebar
Views PDF: 87
INITIAL ASSESSMENT OF FATTY LIVER CONDITION USING LIVER ELASTOGRAPHY (FIBROSCAN) AT THE FUNCTIONAL EXAMINATION DEPARTMENT - NATIONAL HOSPITAL OF TROPICAL DISEASES
Main Article Content
Abstract
Background: Metabolic Associated Fatty Liver Disease (MAFLD) is a new term proposed by the Asian Pacific Association for the Study of the Liver in 2021. The diagnostic criteria for MAFLD are not dependent on the amount of alcohol consumed by the patient and can be applied in the clinical symptoms, non-invasive methods(Fibroscan).
Subjects and methods: Assessment of the prevalence of metabolic-associated fatty liver disease (MAFLD) at the National Hospital of Tropical Diseases. 520 patients were included in this study by a
cross-sectional descriptive in July 2024.
Results: The prevalence of fatty liver disease was 37.31%, and the prevalence of MAFLD was 25.77%. The prevalence of MAFLD in males was 30.72%, higher than in females, 18.69% respectively. The average
age of MAFLD patients was 43.50±13.82, the most patients are between 31- 60 years old. The proportion of hepatitis B patients diagnosed with MAFLD was 24%, while 13% of hepatitis C patients were diagnosed
with MAFLD. Among patients without viral hepatitis, the prevalence of MAFLD was 32%. Hepatitis B patients with MAFLD accounted for 63%, nearly double that of the non-viral group at 34%. The prevalence
of MAFLD in patients with hepatitis C and A was low, at only 1%. The average BMI of the MAFLD group was 24.99 ± 2.42, with 97% of MAFLD patients being overweight with a BMI ≥ 23.
Conclusion: The prevalence of metabolic-associated fatty liver disease (MAFLD) in Vietnamese individuals in this study was 25.77%, which is lower than the global average of 38.77%, the Asian average of 36.31%, and similar to the Asia-Pacific region's average of 29.62%.
Article Details
Keywords
Fibroscan, fatty liver, liver elastography metabolic associated fatty liver disease, MAFLD
References
2. Trần Thị Khánh Tường và Trần Hoàng Đăng Khoa. Hướng dẫn của Hiệp hội Nghiên cứu bệnh gan châu Á Thái Bình Dương trong chẩn đoán và điều trị bệnh gan nhiễm mỡ liên quan chuyển hóa. 4, không biết chủ biên: Trường Đại học Y khoa Phạm Ngọc Thạch, 2022, Tạp chí Y Dược học Phạm Ngọc Thạch, Tập 1, trang 65-75.
3. M, Eslam, et al. 6, 2020. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease, Hepatology International, Vol. 14, pp. 889-919.
4. Võ Văn Huy và Bùi Hữu Hoàng. Thuật ngữ mới: Bệnh gan nhiễm mỡ liên quan rối loạn chuyển hóa. Hồ Chí Minh: Khoa Tiêu hóa Bệnh viện Đại học Y Dược TP. Hồ Chí Minh, 2022.
5. Chan, Kai En, et al. 9, 2022. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals., The Journal of Clinical Endocrinology & Metabolism, Vol. 107, pp. 2691-2700.
6. M, Eslam, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. 1, s.l. : Elsevier BV, 2020, Journal of Hepatology, Vol. 73, pp. 202-209.
7. T, Kawaguchi, et al. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. 2, s.l.: Clin Mol Hepatol, 2022, Vol. 28, pp. 150-163.